INTRODUCTION
============

The prevalence of asthma and allergic disease has increased substantially during the past three or four decades.[@B1],[@B2] Although it has been stabilized or has decreased in most high-prevalence countries (such as English-speaking countries) since 2000, its prevalence is still increasing in population-dense countries in Africa, Latin America and parts of Asia.[@B3],[@B4] Overall, the global burden of asthma is continuing to rise.

The hygiene/old friends hypothesis was proposed to explain the rise in the prevalence of asthma/allergy.[@B5] This hypothesis states that an increase in the prevalence of asthma/allergy is related to diminished exposure to infections and certain relatively harmless environmental organisms or components that the immune system has learned to tolerate.[@B6] Many investigators, including our group,[@B7]-[@B12] have shown that *Mycobacterium bovis* bacille Calmette-Guérin (BCG) and other mycobacterial infections suppress airway hyperresponsiveness (AHR) and eosinophilic inflammation, likely through a T-helper 1 (Th1) or regulatory T cell (Treg) response. Furthermore, we found that BCG and *M. tuberculosis* culture supernatants also suppressed asthmatic reactions.[@B13]

The antigen 85 complex (Ag85) is a major constituent of the secreted proteins of *M. tuberculosis* and BCG that can induce interferon (IFN)-γ secretion from Th1 cells.[@B14] 38-kDa protein is also actively secreted from *M. tuberculosis*[@B15] and stimulates IFN-γ secretion.[@B16] MPB70, another protein that induces IFN-γ production, is a major secreted protein of BCG but is only secreted in small quantities from *M. tuberculosis*.[@B17] This study aimed to determine which of the enriched secretory proteins of mycobacteria have therapeutic effects on asthma.

MATERIALS AND METHODS
=====================

Experimental animals
--------------------

Specific pathogen-free, 6-week-old female BALB/c mice (Daehan BioLink, Eumsung, Korea) were fed standard mouse chow and given water *ad libitum* in an animal care room at Chonnam National University Medical School, Korea. Animal care and treatment followed the guidelines of the Chonnam National University Research Institute of Medical Sciences and the study was approved by the Chonnam National University Institutional Animal Care and Use Committees (CNU IACUC-H-2009-9). Mice were divided into nine groups: one normal control group, one asthma control group, one live BCG-treated group (*n*=10 per group), and six mycobacterial secretory protein-treated groups (*n*=8 per group).

Study design
------------

Mice were sensitized and provoked with ovalbumin (Grade V; Sigma-Aldrich, St. Louis, MO, USA), and those that developed AHR to methacholine (Sigma) were selected as the experimental animals, as described previously ([Fig. 1](#F1){ref-type="fig"}).[@B18] AHR was defined as airway sensitivity \>95% of the confidence interval of the non-sensitized normal control group, and the asthma threshold was 16.3 mg/mL. Mice with established AHR were treated intraperitoneally with live BCG or mycobacterial secretory proteins. One week after treatment, they underwent a second provocation test with ovalbumin, followed by a methacholine challenge test, and then were sacrificed so that inflammatory cell numbers in bronchoalveolar lavage (BAL) fluid and around bronchi (\<500 µm), and cytokine levels in the splenocyte culture supernatants, could be quantified.

Ovalbumin sensitization and provocation, and administration of mycobacterial proteins
-------------------------------------------------------------------------------------

Mice were sensitized through two intraperitoneal injections of 200 µL phosphate-buffered saline (PBS; BioWhittaker™, MD, USA) containing 20 µg ovalbumin and 2.25 mg aluminum hydroxide (Imject Alum; Pierce Biotechnology, Rockford, IL, USA) 2 weeks apart. One week after the second sensitization, the mice were provoked with 1% ovalbumin aerosol using an Ultra-Neb ultrasonic nebulizer (DeVilbiss, Somerset, PA, USA) in an OCP3000 animal body plethysmograph (All Medicus, Anyang, Korea) for 30 minutes per day for three successive days. The normal control group was sensitized and provoked with PBS alone.

Pathogenic *M. tuberculosis* H37Rv (ATCC 27294) and *M. bovis* BCG (Tokyo 172 strain; Korean National Tuberculosis Association, Seoul, Korea) were cultured at 37℃as surface pellicles on Sauton\'s medium. After 6 weeks, the bacilli were removed by filtration through filter paper. The culture supernatants were sequentially sterilized using membrane filters (pore size 1.2 and 0.2 µm) and concentrated by ultrafiltration (Amicon Centriprep-10, Millipore, Billerica, MA, USA).

Ag85 (0.632 mg/mL) and 38-kDa protein (0.95 mg/mL) were purified from the culture supernatants of *M. tuberculosis*, as described previously.[@B15],[@B19],[@B20] MPB70 protein (1.8 mg/mL) from BCG culture supernatants was purified by a two-step process: hydroxylapatite chromatography followed by anion-exchange chromatography. Briefly, a 50%-80% ammonium sulfate precipitate of BCG culture filtrate was dissolved and dialyzed against 1 mM potassium phosphate buffer (PB, pH 7.0), loaded to a column of hydroxylapatite equilibrated with 1 mM PB, and eluted with 1 mM PB (because MPB70 was not retained on the column). Further purification was performed by anion-exchange chromatography using DEAE-Sepharose CL-6B. MPB70 protein was eluted with 0 to 50 mM NaCl in 20 mM Tris-HCl (pH 8.0). The purified proteins were dialyzed against PBS, filter sterilized, and frozen at -80℃. Protein concentrations were determined using a protein assay kit (Pierce) with bovine serum albumin as the standard.

To prepare a live bacterial stock, BCG was cultured at 36℃ for 3 weeks in a sealed 1:1 semisolid mixture of Middlebrook 7H10 agar (Becton Dickinson, Cockeysville, MD, USA) and Middlebrook 7H9 broth (Becton Dickinson) supplemented with 10% oleic acid-albumin-dextrose-catalase (Becton Dickinson). Colonies were counted before preparation of the inoculum. Live BCG (2×10^5^ CFUs) or purified mycobacterial secretory proteins (4 or 20 µg) were administered intraperitoneally to mice with established AHR.

Lung function tests
-------------------

Airway responsiveness to methacholine was measured using the OCP3000 body plethysmograph, as described previously.[@B21] Briefly, the animals inhaled PBS aerosol and then progressively doubled concentrations of methacholine (starting from 3.125 mg/mL and increasing to 100 mg/mL at 24-hour after the final ovalbumin inhalation challenge). Aerosols were generated using an Ultra-Neb nebulizer, and 3 mL solution was aerosolized for 3 minutes. Enhanced pause (P~enh~) was used to represent airway resistance. The methacholine concentration required for a 200% increase in P~enh~ from the post-saline value (PC~200~), the maximal response to methacholine (Maximal P~enh~), and the slope of the methacholine dose-response curve (by linear regression) (DRS) were calculated as indices of airway sensitivity, excessive airway narrowing, and airway reactivity, respectively. As a three-fold improvement in PC~20~ is considered significant in occupational asthma,[@B22] the fold increase in PC~200~ (i.e., ratio of second PC~200~ value to first PC~200~ value) was calculated to evaluate the degree of improvement after treatment.

Analysis of cells in BAL fluid and lung tissue
----------------------------------------------

Forty-eight hours after the last ovalbumin provocation, the mice were sacrificed by intraperitoneal injection of 5 mg/kg thiopental sodium. BAL samples were taken, and total and differential cell counts in the BAL fluid were determined, as described previously.[@B21] Briefly, the lungs were lavaged with 3.6 mL cold 0.9% saline via the trachea. After counting total cells, cytospin preparations (CF-120; Sakura Fine-Technical, Tokyo, Japan) were stained with Diff-Quick (International Reagents, Kobe, Japan). The percentage of each cell type was calculated from the average of 300 consecutive cells counted on each of two slides (magnification, ×400).

The left lung was fixed in 4% formalin and embedded in paraffin for histopathological analysis. The embedded tissue was sectioned to a thickness of 4 µm and stained with hematoxylin-eosin and periodic acid-Schiff. Small airways (circumference \<500 µm) were selected[@B23] and numbers of eosinophils, lymphocytes, and neutrophils within the peribronchial area from the basement membrane to a depth of 100 µm were determined using a Nikon microscope using AnalySIS® Pro image analysis software (Soft Imaging System GmbH, Münster, Germany) and expressed as number of cells/mm^2^.[@B24] Goblet cell hyperplasia was evaluated according to a 5-point scoring system (0-4) as follows: 0, no goblet cells; 1, \<25%; 2, 25%-50%; 3, 50%-75%; and 4, ≥75%.[@B25]

Cytokine assays
---------------

Splenocyte culture and cytokine measurements were performed as described previously.[@B21] Briefly, splenocytes were cultured in RPMI 1640 medium (BioWhittaker, Walkersville, MD, USA) supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA) and a 1% penicillin-streptomycin-amphotericin B mixture (BioWhittaker), and were stimulated with 2.5 µg/mL concanavalin A (Sigma) for 48 hours. IFN-γ, IL-5, and IL-17A concentrations in the supernatants of stimulated splenocytes were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits (BioLegend, Inc., San Diego, CA, USA). The sensitivities of the assays for IFN-γ, IL-5, and IL-17A were 4, 8, and 7.8 pg/mL, respectively.

Statistical analysis
--------------------

PC~200~ values were log10-transformed before analysis, and all data are expressed as the mean±SEM. The Kruskal-Wallis test and Mann-Whitney *U* test were used to determine the significance of the intergroup differences, and the Wilcoxon signed-rank test was used to determine the significance of the intragroup differences. Associations between variables were examined using Spearman\'s rank correlation coefficient. A *P* value of \<0.05 was considered statistically significant.

RESULTS
=======

Methacholine-AHR
----------------

The P~enh~ values after PBS inhalation in the treatment groups were not significantly different than those in the asthma control group either before or after the treatment with live BCG or mycobacterial secretory proteins. In addition, the pre-treatment PC~200~, Maximal P~enh~, and DRS values in the treatment groups were not significantly different than those in the asthma control group ([Table 1](#T1){ref-type="table"}). However, treatment with BCG or mycobacterial secretory proteins, but not PBS, significantly improved airway sensitivity (PC~200~). While the maximal P~enh~ value was only significantly reduced in the 38-kDa protein-treated group, the DRS was significantly reduced in animals treated with BCG, 4 µg Ag85, or 4 µg 38-kDa protein. The fold increase in PC~200~ value after treatment (second PC~200~ value/first PC~200~ value) was significantly higher in the BCG-treated group (1.44±0.09) than in the asthma control group (1.06±0.06) (*P*\<0.01), and was also significantly higher in all groups treated with mycobacterial secretory proteins. The fold increases in PC~200~ value in the mycobacterial secretory protein-treated groups were not significantly different than those in the BCG group.

The PC~200~ value after treatment was significantly lower in the asthma control group than in the normal control group ([Fig. 2](#F2){ref-type="fig"}). The PC~200~ values in all treatment groups were significantly higher than in the asthma control group. Similarly, the maximal P~enh~ and DRS values were significantly higher in the asthma control group than in the normal control group. In addition, the values in the treatment groups, except for maximal P~enh~ values in the 4 µg MPB70 and 20 µg 38-kDa protein groups and for DRS values in the 20 µg MPB70 and 20 µg Ag85 groups, were significantly lower than those in the asthma control group. Compared to the normal control group, all treatment groups showed significant differences in PC~200~ and maximal P~enh~ values. However, the DRS values for the BCG, 4 µg Ag85, and 4 µg 38-kDa protein groups were not significantly different than those for the normal control group.

Cells in BAL fluid and lung tissue
----------------------------------

The proportion of eosinophils in the BAL fluid was significantly higher in the asthma control group than in the normal control group, and significantly lower in all treatment groups than in the asthma control group. However, the eosinophil proportions in all of the treatment groups were significantly higher than that in the normal control group (data not shown). Similarly, the number of eosinophils in the peribronchial tissue was significantly higher in the asthma control group than in the normal control group, and significantly lower in all treatment groups than in the asthma control group ([Fig. 3](#F3){ref-type="fig"}). Numbers of neutrophils/lymphocytes in all treatment groups were not significantly different than those in the asthma control group. In addition, the proportion of goblet cells in the bronchial epithelium was significantly higher in the asthma control group than in the normal control group, and all treatment groups showed a significantly lower proportion of goblet cells compared to the asthma control group ([Fig. 3](#F3){ref-type="fig"}). However, peribronchial eosinophil numbers and goblet cell proportions were significantly higher in all treatment groups than in the normal control group.

Concentrations of cytokines in splenocyte culture supernatants
--------------------------------------------------------------

In the supernatants of concanavalin A-stimulated splenocytes, the IFN-γ level was significantly lower (499±58 vs. 860±97 pg/mL, *P*\<0.05) and the IL-5 level significantly higher (211±81 vs. 90±10, *P*\<0.001) in the asthma control group than in the normal control group, resulting in a significantly lower IFN-γ/IL-5 in the asthma control group (2.8±0.5 vs. 9.8±1.1, *P*\<0.001) ([Fig. 4](#F4){ref-type="fig"}). The IFN-γ/IL-5 ratio was significantly higher in the groups treated with BCG (5.9±1.1, *P*\<0.05), 4 µg MPB70 (5.6±1.2, *P*\<0.05), and 4 µg 38-kDa protein (5.0±0.8, *P*\<0.05) compared to the asthma control group. The IFN-γ/IL-5 ratio was significantly lower in the group treated with 4 µg Ag85 (3.2±0.4, *P*\<0.05) than in the 4 µg MPB70 group. The IFN-γ/IL-5 ratios for all treatment groups were significantly lower than that for the normal control group. The IL-17A level was significantly higher in the asthma control group than in the normal control group (171.0±22.7 vs. 73.8±7.1 pg/mL, *P*\<0.01). However, IL-17A levels in all treatment groups, while significantly higher than that in the normal control group, were not significantly different than that in the asthma control group.

For all subjects, the IFN-γ/IL-5 ratios in the splenocyte culture supernatants were significantly associated with AHR, peribronchial eosinophil, and neutrophil numbers, and goblet cell hyperplasia ([Table 2](#T2){ref-type="table"}). IL-17A level showed a significant relationship with maximal airway narrowing, peribronchial eosinophil numbers, and goblet cell hyperplasia, and was also significantly correlated with IL-5 level (r=0.379, *P*\<0.001).

DISCUSSION
==========

Treatment with mycobacterial secretory proteins had therapeutic effects on AHR and eosinophilic airway inflammation in mice. These results are consistent with those of previous studies showing that mycobacteria such as BCG have suppressive effects on asthma.[@B7]-[@B9],[@B11],[@B13],[@B21],[@B26] However, whole BCG bacteria, even if heat-killed, could not be repeatedly administered to patients with asthma due to side effects.[@B27] The results of this study suggest that mycobacterial secretory proteins such as Ag85, 38-kDa protein, and MPB70, which may have fewer side effects than whole bacteria, may be effective for the treatment of asthma as a result of suppression of AHR and eosinophilic airway inflammation. In our previous study,[@B13] heat-killed preparations of BCG and *M. tuberculosis* did not effectively suppress airway sensitivity, while Shirtcliffe et al.[@B27] reported that heat-killed BCG had no therapeutic effect on patients with asthma. However, because both BCG and *M. tuberculosis* culture supernatants effectively suppressed asthmatic reactions in our previous study,[@B13] and because secretory components in culture supernatants effectively suppressed asthmatic reactions in the present study, it is anticipated that mycobacterial secretory proteins would be effective for treating human asthma as well.

The mycobacterial cell wall glycolipids lipoarabinomannan (LAM) and phosphatidylinositol mannan (PIM) can suppress airway eosinophilia through IL-10 production by T cells.[@B28] In addition, *M. tuberculosis* chaperonin 60.1 can also suppress airway eosinophilia and methacholine-AHR.[@B29] Mannose-capped LAM from *M. bovis* BCG Tokyo-172 enhances the differentiation of human peripheral blood naïve CD4 T cells into Th1 cells.[@B30] Mannose-capped LAM[@B31] and chaperonin 60.1[@B29] from *M. tuberculosis* can suppress asthmatic reactions through Treg cell induction. Thus, many mycobacterial cell wall components seem to have therapeutic effects on asthma through the above mechanisms. However, because heat-killed mycobacteria were ineffective against AHR in our previous study,[@B13] and because Major et al.[@B32] also showed that heat-killed BCG was less effective in suppressing airway eosinophilia than live BCG, these mycobacterial cell wall components seem to be heat-labile. Means et al.[@B33] showed that a cell-associated mycobacterial factor that was distinct from LAM and that mediated Toll-like receptor (TLR)4-dependent activation was heat-sensitive, while a factor in the culture supernatant that activated cells in a TLR2-dependent manner was heat-stable. The mycobacterial secretory proteins in this study might be such heat-stable mycobacterial factors.

The Ag85 complex, which consists of secreted proteins from *M. tuberculosis*, is composed of Ag85A, Ag85B, and Ag85C, of which Ag85A and Ag85B induce a strong Th1-like response.[@B34] Wu et al.[@B35] showed in 2009 that an Ag85B DNA vaccine suppressed eosinophilic airway inflammation in a murine model of asthma, and Mori et al.[@B36] reported that Ag85B suppressed Th2 cytokine-mediated acute-phase atopic inflammatory reactions by increasing Foxp3^+^ Treg cell numbers in an atopic dermatitis mouse model. Because 38-kDa protein[@B16] and MPB70[@B17] induce IFN-γ production, they may also be effective for treating asthma. To the best of our knowledge this study is the first to prove it.

In a large epidemiological study, an increase in tuberculosis notification rates of 25 per 100,000 was associated with a 4.7% decrease in the prevalence of wheezing,[@B37] while BCG vaccination had only a weak protective effect against asthma.[@B38] Therefore, secretory proteins from *M. tuberculosis* may have a strong therapeutic effect against asthma compared to BCG. In this study, 38-kDa protein and Ag85 of *M. tuberculosis* suppressed all three components of AHR (airway sensitivity, excessive airway narrowing, and airway reactivity), while MPB70 of BCG suppressed only airway sensitivity. Because *M. tuberculosis* induces the production of four times more IFN-γ than does BCG,[@B39] we speculated that secretory proteins of *M. tuberculosis* would induce the production of greater amounts of IFN-γ than do BCG proteins, but this was not the case. The IFN-γ/IL-5 ratio was higher in the MPB70-treated group than in the Ag85-treated group in this study. Hence, the superior effect of *M. tuberculosis* on AHRmay not primarily depend on IFN-γ but Treg cells. However, further studies are required to confirm this. In this study, the lower dose of 38-kDa protein and Ag85 from *M. tuberculosis* tested (4 µg) was more effective at suppressing AHR than the higher dose (20 µg), similar to the observation of Lin et al.,[@B18] who found that addition of high-dose dehydroepiandrosterone to BCG reduced the efficacy of BCG. Although the reason for this paradoxical response is not clear, a plausible explanation can be found in a report by Yoshida et al.,[@B40] who showed that ongoing AHR following allergen challenge in IFN-γ-deficient mice was resolved by treatment with IFN-γ for 1 week, but aggravated by treatment for 4 weeks. Thus, the superfluous IFN-γ in mice treated with higher doses might not have a beneficial effect on asthma, but may instead be detrimental, even if it is transient, as brief Th1-related exacerbation of asthma may follow respiratory viral infection.[@B41] Further investigation is necessary to determine the proper doses of mycobacterial secretory proteins for effective treatment of asthma.

Although the changes in the IFN-γ/IL-5 ratio after treatment did not coincide well with the effects of mycobacterial component treatment on AHR or airway cells, the ratios tended to be higher in the treatment groups than the asthma control group, and the IFN-γ/IL-5 ratio was significantly correlated with AHR, airway eosinophilia, and goblet cell proportion. These results are consistent with previous reports showing that mycobacteria[@B7]-[@B11],[@B21],[@B26],[@B42] and their components[@B29] produced suppressive effects by shifting the Th1/Th2 balance to Th1. Because Treg cells can suppress airway eosinophilia through suppression of both Th1 and Th2 cells by secreting IL-10 and transforming growth factor-β,[@B12] it is necessary to check these cytokine levels. However, we were unable to do this because they were undetectable in a preliminary study. Meanwhile, IL-17A was significantly associated with maximal airway narrowing and goblet cell proportion in this study. IL-17 produced by Th17 cells was recently reported to mediate neutrophilic airway inflammation and AHR.[@B43] In contrast to this previous report,[@B43] IL-17A levels were associated with peribronchial infiltration of eosinophils, but not neutrophils, in the present study. IL-17A levels showed a significant relationship with IL-5 levels, corroborating a report by Bullens et al.,[@B44] who showed that IL-17 mRNA level was correlated with IL-5 mRNA level in sputum from patients with asthma. Thus, while its role in asthma is unclear, IL-17A seems unlikely to promote the therapeutic effects of mycobacterial secretory proteins.

Various mycobacterial lipoproteins are recognized by TLR2 in association with TLR1/TLR6 or by TLR4 on the surface of antigen-presenting cells (APCs) and induce naïve T cells to differentiate, mainly into Th1/Treg cells (immune polarization), with the help of IL-12 and IL-10 secreted from APCs.[@B45] Lipomannan, the precursor of LAM, is recognized by TLR2, ManLAMs by the mannose receptor or DC-SIGN, PIM by TLR2,[@B46],[@B47] chaperonin 60.1 by TLR4,[@B29] and 38-kDa glycolipoprotein by both TLR2 and TLR4. However, for Ag85, there is only one report showing that it does not stimulate TLR2 or TLR4,[@B48] and for MPB70, no pattern recognition receptor has yet been identified. Therefore, further investigation in this area is necessary.

MPB70, a BCG secretory protein, was as effective as live BCG for the treatment of established asthma in this study. In our previous study,[@B21] among the various strains of BCG, the Tokyo 172 strain, but not the Pasteur F1173P2, Tice, or Connaught strains, significantly suppressed AHR. Because MPB70 is present at high concentrations in Tokyo strain culture supernatants, but only in very small amounts in Pasteur, Tice, and Copenhagen strain culture supernatants,[@B49] the strain-dependency of the effects of BCG on asthma may be affected by differences in MPB70 levels between the various strains.

Because cytokine levels in the splenocyte culture supernatants may not exactly reflect the local airway status, it would be better to measure cytokine levels directly in the airways. We tried for the first time to detect cytokine mRNAs in the lungs of mice by semi-quantitative RT-PCR, but the results were disappointingly not interpretable and we therefore did not present them in this study. We did not obtain any data on innate immunity because we have no experience with TRL studies. Further experiments on this are desirable in the future. Although Hamelmann et al.[@B50] reported that an increase in P~enh~ in response to inhaled methacholine is a valid indicator of AHR, AHR measurements must be validated using a more rigorous method.

In conclusion, mycobacterial secretory proteins were, like live BCG, effective for the treatment of established asthma, and increased the IFN-γ/IL-5 ratio. Thus, allergic asthma can be effectively treated with mycobacterial secretory proteins.
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![IFN-γ/IL-5 ratios in splenocyte culture supernatants were higher in the BCG, 4 µg MPB70, and 4 µg 38-kDa protein groups than in the asthma control group. ^\*^*P*\<0.05, ^†^*P*\<0.001 vs. the asthma control group.](aair-4-214-g004){#F4}

###### 

Airway sensitivity (PC~200~), excessive airway narrowing (maximal P~enh~), and airway reactivity (DRS) in mice before and after treatment with BCG or mycobacterial secretory proteins
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Data are expressed as the mean±standard error.

PC~200~, concentration of methacholine required for a 200% increase in enhanced pause (P~enh~) index from baseline; DRS, dose-response slope; BCG, bacille Calmette-Guérin. ^\*^*P*\<0.05, ^†^*P*\<0.01 vs. pretreatment values.
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Correlation coefficients for cytokine levels in splenocyte culture supernatants and markers of asthmatic airway reactions in mice treated with BCG or mycobacterial secretory proteins
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BCG, bacille Calmette-Guérin.

^\*^*P*\<0.05, ^†^*P*\<0.01, ^‡^*P*\<0.001.
